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Since ceftriaxone was introduced into the Malawian national formulary in 2005, there 10 
have been rapid increases in the incidence of extended-spectrum beta-lactamase 11 
producing Enterobacteriaceae (ESBL-E), which are often untreatable due to a lack of 12 
locally available alternative treatment options.[1] Carbapenem antibiotics, the 13 
treatment of choice for invasive ESBL-E, were introduced to the Malawian essential 14 
medicine list in 2015, but remain sporadically available even in tertiary level facilities, 15 
frequently curtailing empiric therapeutic regimens prior to clinical improvement or 16 
completion of a course. Surveillance of bloodstream infection via automated blood 17 
culture (Biomerieux, France) has yet to detect any carbapenemase-producing 18 
organisms in Malawi[2], however , we report the detection of an NDM-5 producing E. 19 
coli, despite the low availability of carbapenems. 20 
 21 
On 19 March 2018, a 67-year-old man attended Queen Elizabeth Central Hospital 22 
(QECH), Blantyre, with fever, headache and cough of a week’s duration. He was 23 
HIV-infected and stable on antiretroviral therapy, but was not taking co-trimoxazole 24 
preventative therapy. He had received no antibiotics in the previous month and had 25 
no history of foreign travel. He had not been admitted to hospital in the previous 6 26 
months. Malaria rapid diagnostic test was negative for P. falciparum and aerobic 27 
culture of blood and cerebrospinal fluid yielded no pathogens. He was treated with 28 
seven days of intravenous ceftriaxone, made an uneventful recovery and was 29 
discharged after seven days of admission. 30 
 31 
As part of an observational study investigating acquisition of gut mucosal carriage of 32 
ESBL-E during admission to QECH (approved by ethics committees of the Malawi 33 
College of Medicine [P.11/16/2063] and Liverpool School of Tropical Medicine [16-34 
062]), the patient’s stool was selectively cultured for ESBL-E on CHROMagar ESBL 35 
media (CHROMagar, Paris, France) on admission and on day seven of hospital 36 
admission. Morphologically distinct bacterial colonies growing on CHROMagar were 37 
confirmed to be ESBL producers using combination disc testing, speciation was 38 
carried out using the API system (Biomerieux, France) and antimicrobial sensitivities 39 
were determined using disc diffusion testing as per British Society of Antimicrobial 40 
Chemotherapy (BSAC) guidelines. All analyses were undertaken in the Malawi-41 
Liverpool Wellcome Trust clinical laboratory, which subscribes to the UK National 42 
External Quality Assessment Service (NEQAS). 43 
 44 
An ESBL-producing Escherichia coli was isolated from stool collected on day 7 of 45 
hospital admission, resistant to ciprofloxacin, co-trimoxazole, gentamicin, ceftriaxone 46 
and meropenem, with sensitivity to amikacin and chloramphenicol. Minimum 47 
inhibitory concentration to meropenem was 4mg/L by E-test (bioMerieux, France), 48 
and an ESBL/carbapenemase high resolution melt (HRM) PCR  assay confirmed the 49 
presence of a New-Delhi metallo-beta-lactamase gene (NDM).[3] 50 
 51 
In view of this resistance pattern, genomic DNA was extracted using the Qiagen 52 
DNA mini kit (Hilden, Germany) as per the manufacturer’s instructions, and paired-53 
end short-read whole genome sequencing was undertaken at the Wellcome Trust 54 
Sanger Institute using Illumina HiSeq-X10. De novo assembly was performed using 55 
SPAdes V3.11.0 followed by annotation with Prokka v1.5; assemblies were 56 
deposited in GenBank (accession number ERS2493547). Multi-locus sequence 57 
typing (MLST) using ARIBA V2.12.1 showed that this bacterium belonged to E. coli 58 
Sequence Type 2083, and a search for known antimicrobial resistance genes 59 
against the Comprehensive Antibiotic Resistance Database again using ARIBA 60 
V2.12.1 confirmed the presence of blaNDM-5 as well as other genes encoding 61 
products conferring resistance to aminoglycosides (aac(3)-IIa, aac(6’)-IIb, aph(3’)-Ib, 62 
aph(6)-Id, aadA5), tetracyclines (tet(R), tet(A), tet(D)), trimethorprim (dfrA17) and 63 
suphonamides (sul1, sul2) as well as a CMY-42 ampC and blaTEM-95 narrow-64 
spectrum beta lactamase, but no plasmid-mediated quinolone resistance. 65 
 66 
Plasmid replicons were identified using ARIBA v2.1.2.1 and the PlasmidFinder 67 
database[4]. The blaNDM-5 gene was carried on a partially assembled Inc-X3 plasmid, 68 
which had 99% identity with a previously sequenced plasmid, pNDM-MGR194, a 69 
46.2 kbp blaNDM-5 containing Inc-X3 plasmid found in India between 2011-13.[5] We 70 
therefore fully assembled the plasmid from our isolate by mapping reads to this 71 
reference using Burrows-Wheeler alignment and found it to be extremely similar, 72 
with only 13 single nucleotide polymorphisms (SNPs) (Figure 1). Since its 73 
identification in India, virtually identical plasmids to pNDM-MGR194 have been 74 
described in humans and animals worldwide, [6] carried by Klebsiella pneumoniae, 75 
Citrobacter freundii and a wide variety of E. coli sequence types - though not 76 
previously ST 2083. There were a number of other plasmid replicons identified in our 77 
isolate: IncFI, IncFIA, IncFIB, IncFII and IncI1. The location of the CMY-42 ampC in 78 
the genome could not be determined, but did not seem to carried on the same 79 
plasmid as the blaNDM-5 gene. 80 
 81 
The admission stool sample was also selectively cultured for ESBL-E using the 82 
same protocol; the patient was found to be colonised with an ESBL-producing E coli 83 
on admission but the admission isolate was distinct in terms of AMR profile and E. 84 
coli sequence type. It was meropenem sensitive on antimicrobial sensitivity testing 85 
and, following whole-genome sequencing, MLST and identification of AMR genes as 86 
above, was found to contain no carbapenemase genes but a blaCTX-M-16 ESBL gene. 87 
It was also not ST 2082 on MLST, but a novel ST, suggesting possible hospital 88 
acquisition of the carbapenemase-producing isolate. 89 
 90 
The rapid emergence of carbapenem resistance in Malawi soon after the introduction 91 
of carbapenems on only a small scale is alarming, and hard to balance with the 92 
growing unmet need for access to this class of antimicrobial due to the problem of 93 
ESBL-E infection. It is likely that sporadic availability of carbapenems, often for 94 
incomplete courses, is creating selection pressure for the dissemination of this 95 
resistance type. This report highlights the urgent need for a holistic and context 96 
specific approach to both hospital infection prevention and control and antimicrobial 97 
stewardship in low-income settings, respecting the need to ensure appropriate 98 




Figure 1: Plasmid pNDM_MGR194 annotated with gene names; location of single 103 
nucleotide polymorphisms (SNPs) identified in the Malawian plasmid shown in inner 104 
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